



Press release

Number of shares and votes in Orexo

Uppsala, Sweden – September 30, 2016 – The number of shares and votes in Orexo AB has changed as a result of the exercise of warrants in connection with the company's incentive programs.

Today, the last trading day of the month, there are in total 34,666,107 shares - whereof 34,531,107 are ordinary shares and 135,000 class C shares - and 34,544,607 votes in the company.

For further information, please contact:

Orexo AB (publ.)

Henrik Juuel, EVP and CFO

Tel: 018 780 88 00

email: ir@orexo.com

Lena Wange, IR & Communications Manager

Tel: 018 780 88 00

email: ir@orexo.com

About Orexo

Orexo is a specialty pharmaceutical company commercializing its proprietary product Zubsolv® for treatment of opioid dependence in the US. Zubsolv is an advanced formulation of buprenorphine and naloxone using Orexo's unique knowledge and expertise in sublingual drug delivery. R&D is focusing on reformulation of known substances to new improved products that meet great unmet medical needs by using its patented proprietary technologies. Orexo's share is listed on Nasdaq Stockholm Exchange Mid Cap (STO: ORX) and is available as ADRs on OTCQX (ORXOY) in the US. Orexo's global headquarters and R&D are based in Uppsala, Sweden.

For more information about Orexo, please visit www.orexo.com or follow us on [Twitter](#) or [LinkedIn](#). For further information about Zubsolv in the US, please visit www.zubsolv.com.

The information was submitted for publication at 6:00pm CET, September 30, 2016